Somewhat Favorable News Coverage Somewhat Unlikely to Impact Celsion (CLSN) Stock Price

News coverage about Celsion (NASDAQ:CLSN) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celsion earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.8531667450901 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have effected Accern’s rankings:

Celsion (NASDAQ:CLSN) traded down $0.08 on Tuesday, hitting $2.52. 828,800 shares of the stock were exchanged, compared to its average volume of 1,618,081. Celsion has a 12-month low of $1.24 and a 12-month high of $9.94.

A number of equities research analysts have issued reports on CLSN shares. Maxim Group reissued a “hold” rating on shares of Celsion in a report on Monday, August 7th. Zacks Investment Research raised shares of Celsion from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Tuesday, August 29th. ValuEngine raised shares of Celsion from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Oppenheimer started coverage on shares of Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $11.90.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Insider Buying and Selling by Quarter for Celsion (NASDAQ:CLSN)

What are top analysts saying about Celsion Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celsion Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit